|
|
|
|
Stem cell therapy has already revolutionized the field of oncology. But where do we go from here? Dr. Robert S. Negrin addresses three key areas of CAR T-cell therapy on the brink of innovation.
|
|
|
|
|
What was once science fiction has moved up to second-line therapy. Dr. Robert Negrin navigates the trajectory of CAR T-Cell Therapy from early HIV therapy to second-line treatment for diffuse large B-cell lymphoma.
|
|
|
|
|
Drugs operating on the GLP-1 axis are rife with potential for use in other interventions. Find out how today’s FDA-approved obesity medications are primed to become tomorrow’s novel treatments across multidimensional states of disease — from diabetes to heart failure.
|
|
|
|
|
Integrating EHR and EDC systems is pivotal to enhancing diversity in oncological clinical trials. This is emphasized by the FDA's draft guidance on Diversity Action Plans, which aims to generate more representative data for medical products.
|
|
|
|
|
What is the curative potential of protein design? In the latest episode of Biorasi's Few & Far Between podcast, Marc Lajoie delves into how de novo proteins can be used to reprogram immune cells.
|
|
|
|
|
|
|
|
|
|
|
